This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
APEN Aktienübersicht
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for gastrointestinal therapeutic endoscopy.
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 0/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
Apollo Endosurgery, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$10.00 |
| 52-Wochen-Hoch | US$10.30 |
| 52-Wochen-Tief | US$3.49 |
| Beta | 2.32 |
| 11 Monat Veränderung | 0.50% |
| 3 Monate Veränderung | 1.11% |
| 1 Jahr Veränderung | 67.79% |
| 33 Jahre Veränderung | 360.83% |
| 5 Jahre Veränderung | 70.94% |
| Veränderung seit IPO | -17.76% |
Aktuelle Nachrichten und Updates
Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?
Apr 03
Is Apollo Endosurgery (NASDAQ:APEN) Weighed On By Its Debt Load?
Nov 30Recent updates
Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?
Apr 03Is Apollo Endosurgery (NASDAQ:APEN) Weighed On By Its Debt Load?
Nov 30Is Apollo Endosurgery (NASDAQ:APEN) Using Too Much Debt?
Aug 05Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings
Aug 04Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?
Mar 02Is Apollo Endosurgery, Inc. (NASDAQ:APEN) Trading At A 20% Discount?
Aug 04Apollo Endosurgery: New Management Bounce Makes Weight Loss Specialist A Buy
Jun 28Is Apollo Endosurgery (NASDAQ:APEN) A Risky Investment?
May 05Apollo Endosurgery EPS beats by $0.05, beats on revenue
May 04A Look At The Intrinsic Value Of Apollo Endosurgery, Inc. (NASDAQ:APEN)
Mar 24What Percentage Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Shares Do Insiders Own?
Mar 03Trade Alert: Neil Gagnon At Apollo Endosurgery, Inc. (NASDAQ:APEN), Has Just Spent US$146k Buying 2.8% More Shares
Feb 10We Think Apollo Endosurgery (NASDAQ:APEN) Has A Fair Chunk Of Debt
Jan 31Assessing Apollo Endosurgery
Dec 27If You Had Bought Apollo Endosurgery's (NASDAQ:APEN) Shares Three Years Ago You Would Be Down 36%
Dec 27Is It Too Late To Consider Buying Apollo Endosurgery, Inc. (NASDAQ:APEN)?
Dec 01Apollo Endosurgery EPS beats by $0.10, beats on revenue
Nov 05Aktionärsrenditen
| APEN | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 0.8% | 1.0% | 1.1% |
| 1Y | 67.8% | 26.6% | 32.2% |
Rendite im Vergleich zur Industrie: APEN exceeded the US Medical Equipment industry which returned -13.3% over the past year.
Rendite vs. Markt: APEN exceeded the US Market which returned -11.4% over the past year.
Preisvolatilität
| APEN volatility | |
|---|---|
| APEN Average Weekly Movement | 0.5% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: APEN has not had significant price volatility in the past 3 months.
Volatilität im Zeitverlauf: APEN's weekly volatility has decreased from 12% to 1% over the past year.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2005 | 202 | Chas McKhann | www.apolloendo.com |
Apollo Endosurgery, Inc.'s Grundlagenzusammenfassung
| APEN grundlegende Statistiken | |
|---|---|
| Marktanteil | US$579.72m |
| Gewinn(TTM) | -US$39.84m |
| Umsatz(TTM) | US$76.86m |
7.5x
Kurs-Umsatz-Verhältnis-14.6x
Kurs-Gewinn-VerhältnisIst APEN zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| APEN Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$76.86m |
| Kosten der Einnahmen | US$34.43m |
| Bruttogewinn | US$42.43m |
| Sonstige Ausgaben | US$82.27m |
| Umsatz | -US$39.84m |
Zuletzt gemeldete Gewinne
Dec 31, 2022
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.69 |
| Bruttomarge | 55.20% |
| Nettogewinnspanne | -51.84% |
| Schulden/Eigenkapital-Verhältnis | 164.7% |
Wie hat sich APEN auf lange Sicht entwickelt?
Historische Performance und Vergleiche